Whole genome analysis using the NASA Ames supercomputer to define risk groups for severe pulmonary disease associated with COVID-19 and other illnesses

In order to identify subgroups of COVID-19 patients who are most at risk of developing Acute Respiratory Distress Syndrome (ARDS), the most devastating complication of COVID-19, we will perform complete genome sequencing on patients who develop ARDS and those who do not. We will use the NASA Ames Supercomputer to perform a variety of correlation analyses, in order to identify high-risk groups based on genetics. The study is expected to result in practical tools for predicting which COVID-19 patients are likely to develop ARDS and therefore which patients are likely to need intensive support, prior to the emergence of severe symptoms. Such tools should help to guide intensive care resource utilization for the sickest patients, to help manage the pandemic. In addition, the study is expected to provide a rational basis for the early testing of novel vaccines and therapeutics in the highest risk groups. This study can be started quickly, and is expected to yield useful preliminary data within just a few weeks.